1. Home
  2. Knowledge Base
  3. References
  4. Antibody therapy targeting CD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts.

Antibody therapy targeting CD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts.

Ngo M, Han A, Lakatos A, Sahoo D, Hachey S, Weiskopf K, Beck A, Weissman I, Boiko A (2016) Antibody therapy targeting CD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts. Cell Rep 16:1701-1716. doi: 10.1016/j.celrep.2016.07.004

Summary: The high rate of metastasis and recurrence among melanoma patients indicates the presence of cells within melanoma that have the ability to both initiate metastatic programs and bypass immune recognition. The authors identified CD47 as a regulator of melanoma tumor metastasis and immune evasion. The study involved antibody-mediated blockade of CD47 coupled with targeting of CD271+ melanoma cells by way of ME20.4-SAP (Cat. #IT-15). Mice bearing human melanoma tumor (M213 or M727) were randomized into four treatment groups with one of those groups receiving treatment with ME20.4-SAP. 1 ug in 50 ul volumes were injected directly into the center mass of the tumor once every 2 days. A therapeutic effect was observed where tumor metastasis in patient-derived xenografts was strongly inhibited when treated with the combination of antibody-mediated blockade of CD47 and targeted with ME20.4-SAP.

Related Products: ME20.4-SAP (Cat. #IT-15)